Anti-Ferritin Light Chain antibody [EPR5259] (ab109019)


  • Product nameAnti-Ferritin Light Chain antibody [EPR5259]
    See all Ferritin Light Chain primary antibodies
  • Description
    Rabbit monoclonal [EPR5259] to Ferritin Light Chain
  • Tested applicationsSuitable for: WB, IP, ICCmore details
    Unsuitable for: Flow Cyt or IHC-P
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    A synthetic peptide corresponding to residues near the N-terminus of Human Ferritin Light Chain.

  • Positive control
    • Human fetal liver, HepG2 and HeLa cell lysates.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.



Our Abpromise guarantee covers the use of ab109019 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 20 kDa.
IP 1/10 - 1/100.
ICC 1/100 - 1/250.
  • Application notesIs unsuitable for Flow Cyt or IHC-P.
  • Target

    • FunctionStores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney.
    • Involvement in diseaseDefects in FTL are the cause of hereditary hyperferritinemia-cataract syndrome (HHCS) [MIM:600886]. It is an autosomal dominant disease characterized by early-onset bilateral cataract. Affected patients have elevated level of circulating ferritin. HHCS is caused by mutations in the iron responsive element (IRE) of the FTL gene.
      Defects in FTL are the cause of neurodegeneration with brain iron accumulation type 3 (NBIA3) [MIM:606159]; also known as adult-onset basal ganglia disease. It is a movement disorder with heterogeneous presentations starting in the fourth to sixth decade. It is characterized by a variety of neurological signs including parkinsonism, ataxia, corticospinal signs, mild nonprogressive cognitive deficit and episodic psychosis. It is linked with decreased serum ferritin levels.
    • Sequence similaritiesBelongs to the ferritin family.
      Contains 1 ferritin-like diiron domain.
    • Information by UniProt
    • Database links
    • Alternative names
      • Ferritin L chain antibody
      • Ferritin L subunit antibody
      • Ferritin light chain antibody
      • Ferritin light polypeptide antibody
      • ferritin light polypeptide like 3 antibody
      • FRIL_HUMAN antibody
      • FTL antibody
      • LFTD antibody
      • NBIA 3 antibody
      • NBIA3 antibody
      see all

    Anti-Ferritin Light Chain antibody [EPR5259] images

    • All lanes : Anti-Ferritin Light Chain antibody [EPR5259] (ab109019) at 1/1000 dilution

      Lane 1 : Human fetal liver lysate
      Lane 2 : HepG2 cell lysate
      Lane 3 : HeLa cells lysate

      Lysates/proteins at 10 µg per lane.

      Predicted band size : 20 kDa

    References for Anti-Ferritin Light Chain antibody [EPR5259] (ab109019)

    This product has been referenced in:
    • Wu T  et al. Expression of Ferritin Light Chain (FTL) Is Elevated in Glioblastoma, and FTL Silencing Inhibits Glioblastoma Cell Proliferation via the GADD45/JNK Pathway. PLoS One 11:e0149361 (2016). WB, IHC, ICC/IF ; Human . Read more (PubMed: 26871431) »

    See 1 Publication for this product

    Product Wall

    Application Western blot
    Sample Mouse Tissue lysate - whole (Liver)
    Gel Running Conditions Reduced Denaturing (4-20%)
    Loading amount 50 µg
    Specification Liver
    Blocking step Rockland fluorescent blocking buffer as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 50% · Temperature: 25°C

    Abcam user community

    Verified customer

    Submitted Jul 07 2015